§ Specialty

Dermatology SEO

Dermatology SEO.

Abstract

Skin-cancer content and Botox content sit at different YMYL thresholds. The Reviews System framework reads ABMS American Board of Dermatology alignment differently per article topic. Prescription drug trade names cross the FDA 21 CFR 202 boundary. Identifiable condition photography requires 45 CFR 164.508 imagery-specific authorization. The site architecture has to carry the split.

Book a diagnostic →

Dermatology sits inside the broader Praxis medical SEO practice. The work integrates with the consent-workflow design, the schema discipline that reserves clinical types for editorial content, the directory reconciliation, and the GBP architecture for dual-tier dermatology practices.

What governs the surface

Four surfaces, two thresholds. Each one has its own workflow.

Medical dermatology and cosmetic dermatology sit at different YMYL thresholds under the Reviews System framework, and the credential alignment differs per article topic. Prescription drug copy and clinical imagery each carry their own regulatory boundary. The four mechanisms below name what the architecture has to separate.

Dual-threshold YMYL: skin cancer at the strictest, cosmetic at less-strict.

The Reviews System 2023+ medical-content framework scales evaluation threshold by topic stakes. Dermatologic oncology content (melanoma, basal cell carcinoma, squamous cell carcinoma, Mohs surgery) sits at the strictest YMYL threshold; the framework reads for practicing-physician reviewer signals, ABMS American Board of Dermatology certification, and dermatologic-oncology fellowship surfacing where the practice has one. Cosmetic-dermatology content (Botox, fillers, laser treatments) sits at a less-strict threshold but still gates on ABMS alignment. We scale citation density and byline-credential surfacing per article topic.

ABMS American Board of Dermatology plus subspecialty fellowships in the chain.

The Physician.sameAs chain reaches the ABMS verification page, the NPPES (NPI registry) entry, and the state medical board licensure profile for every author. Where the practice has board-certified dermatologists with subspecialty fellowships (dermatologic oncology, pediatric dermatology, Mohs surgery), the fellowship credential surfaces in the byline body and resolves through the chain. The Reviews System reads the alignment between article topic and credentialed subspecialty; a general dermatologist authoring melanoma articles is the documented YMYL-demotion pattern.

FDA 21 CFR 202 boundary on prescription drug copy.

A dermatology practice marketing its own services is not advertising a prescription drug, and the FDA fair-balance framework does not bind the practice the way it binds a pharmaceutical manufacturer. When the practice page mentions Accutane, Otezla, Dupixent, Rinvoq, or another prescription drug by trade name, the surface crosses into FDA-regulated promotional copy under 21 CFR 202. State medical board rules and AMA E-9.6.1 still apply on top. Botox and injectable filler trade names follow the same pattern. The page architecture separates condition-education content from prescription-drug-mentioning content.

Clinical-imagery consent under 45 CFR 164.508 specificity.

Identifiable dermatologic-condition photography (skin-cancer lesions, acne pre-and-post, psoriasis on identifiable body locations, surgical scar formation) is the load-bearing proof surface for many dermatology practices. The 45 CFR 164.508 specificity requirement applies to imagery separately from text testimonials. The authorization names what gets disclosed, who receives it, the purpose, the surfaces of use, the duration, the patient's revocation rights. Cosmetic before-and-after galleries share the mechanic with plastic-surgery imagery; clinical condition photography on identifiable skin surfaces shares it too.

Side by side

Dermatology on Praxis versus the cosmetic-template default, on the surfaces where the threshold split matters.

Dermatology practice on Praxis

Dual-threshold YMYL discipline

Dermatology practice on generalist SEO

Single-threshold cosmetic template

Editorial threshold scaling

Dermatologic-oncology content scaled to the strictest YMYL threshold: practicing-physician byline, ABMS American Board of Dermatology alignment, fellowship surfacing where present, PubMed-cited primary literature, specialty-society guideline references (AAD clinical guidelines, NCCN oncology guidelines).

Single editorial threshold across all topics. Skin-cancer articles authored under the same byline pattern as Botox articles. Reviews System framework demotion pattern is the documented outcome.

Author byline architecture

Per-author Physician.sameAs chain to ABMS verification, NPPES, state medical board, plus subspecialty fellowship surfacing in byline body where the topic intersects the fellowship (Mohs surgeon on Mohs articles; dermatologic oncologist on melanoma articles).

Generic agency byline or unspecified physician byline. ABMS chain absent from JSON-LD. Reviews System reads no practicing-physician reviewer signal.

Prescription drug trade names

Accutane, Otezla, Dupixent, Rinvoq, Skyrizi, Cosentyx surfaces architected as FDA 21 CFR 202 promotional copy. Fair-balance pattern applied. State-board rules layered on top.

Trade-name surfaces published as condition-treatment commentary. Fair-balance pattern absent. FDA boundary unread.

Cosmetic injectables and lasers

Botox, Juvederm, Restylane, Dysport surfaces architected as 21 CFR 202 promotional copy. Laser-treatment marketing under AMA E-9.6.1 with per-state cosmetic-advertising overlays. Shared mechanics with the plastic-surgery surface.

Cosmetic surfaces treated identically to medical-dermatology surfaces. Mixed-threshold pages produce regulatory ambiguity at the section level.

Clinical-condition photography consent

Imagery-specific authorization under 45 CFR 164.508 specificity. Identifiable skin-condition photography (acne, psoriasis, skin-cancer lesions, surgical scarring) routed through the workflow before publication.

Condition photography published under generic photo release. 164.508 specificity standard unmet for identifiable clinical imagery.

Schema markup discipline

Commercial pages on MedicalBusiness with availableService nodes. MedicalProcedure schema reserved for editorial content authored by ABD-certified physicians. MedicalCondition reserved for educational hub pages, never on commercial pages.

MedicalCondition or MedicalProcedure applied to commercial pages selling treatments. Spammy-structured-data manual-action pattern is the documented outcome.

GBP sub-category selection

Per-location GBP with Dermatologist as primary plus Mohs Surgeon, Skin Cancer Treatment Center, or Medical Spa as secondary categories depending on the practice's service mix.

Single Dermatologist category across all locations. Sub-category surface unused. Local-pack relevance leaking to practices with denser sub-category specification.

Dermatology practice on Praxis

Dual-threshold YMYL discipline

Editorial threshold scaling: Dermatologic-oncology content scaled to the strictest YMYL threshold: practicing-physician byline, ABMS American Board of Dermatology alignment, fellowship surfacing where present, PubMed-cited primary literature, specialty-society guideline references (AAD clinical guidelines, NCCN oncology guidelines).
Author byline architecture: Per-author Physician.sameAs chain to ABMS verification, NPPES, state medical board, plus subspecialty fellowship surfacing in byline body where the topic intersects the fellowship (Mohs surgeon on Mohs articles; dermatologic oncologist on melanoma articles).
Prescription drug trade names: Accutane, Otezla, Dupixent, Rinvoq, Skyrizi, Cosentyx surfaces architected as FDA 21 CFR 202 promotional copy. Fair-balance pattern applied. State-board rules layered on top.
Cosmetic injectables and lasers: Botox, Juvederm, Restylane, Dysport surfaces architected as 21 CFR 202 promotional copy. Laser-treatment marketing under AMA E-9.6.1 with per-state cosmetic-advertising overlays. Shared mechanics with the plastic-surgery surface.
Clinical-condition photography consent: Imagery-specific authorization under 45 CFR 164.508 specificity. Identifiable skin-condition photography (acne, psoriasis, skin-cancer lesions, surgical scarring) routed through the workflow before publication.
Schema markup discipline: Commercial pages on MedicalBusiness with availableService nodes. MedicalProcedure schema reserved for editorial content authored by ABD-certified physicians. MedicalCondition reserved for educational hub pages, never on commercial pages.
GBP sub-category selection: Per-location GBP with Dermatologist as primary plus Mohs Surgeon, Skin Cancer Treatment Center, or Medical Spa as secondary categories depending on the practice's service mix.

Dermatology practice on generalist SEO

Single-threshold cosmetic template

Editorial threshold scaling: Single editorial threshold across all topics. Skin-cancer articles authored under the same byline pattern as Botox articles. Reviews System framework demotion pattern is the documented outcome.
Author byline architecture: Generic agency byline or unspecified physician byline. ABMS chain absent from JSON-LD. Reviews System reads no practicing-physician reviewer signal.
Prescription drug trade names: Trade-name surfaces published as condition-treatment commentary. Fair-balance pattern absent. FDA boundary unread.
Cosmetic injectables and lasers: Cosmetic surfaces treated identically to medical-dermatology surfaces. Mixed-threshold pages produce regulatory ambiguity at the section level.
Clinical-condition photography consent: Condition photography published under generic photo release. 164.508 specificity standard unmet for identifiable clinical imagery.
Schema markup discipline: MedicalCondition or MedicalProcedure applied to commercial pages selling treatments. Spammy-structured-data manual-action pattern is the documented outcome.
GBP sub-category selection: Single Dermatologist category across all locations. Sub-category surface unused. Local-pack relevance leaking to practices with denser sub-category specification.

Updated 2026-05-28

How we engage

Diagnostic, then monthly retainer. Four phases, each scoped against cited deliverables.

Weeks 0-2

Diagnostic

We read your Search Console data, your traffic data, your current Schema.org markup, your physician author bylines, your testimonial pages, and your directory-profile completeness. The diagnostic comes back with the load-bearing pages, the dead weight, the YMYL-fragile content, and the entity-graph gaps. For multi-location groups, we add a GBP audit per practicing location.
Weeks 2-6

Schema and author layer

We build the MedicalBusiness and Physician schema layer with sameAs chains to NPI registry, ABMS verification, and state medical board profiles. Author bylines surface ABMS specialty and active state license alignment. CPT-aligned service pages where the procedure mix supports it. The schema layer reflects what each page actually is, MedicalCondition / MedicalProcedure types reserved for the editorial layer.
Weeks 4-8

Reviews System alignment

Editorial content rebuilt against the Reviews System 2023+ medical-content framework. Practicing-physician reviewer signals on first-party content. PubMed-cited primary literature replacing health-magazine summaries. Topic-to-specialty alignment in every author byline (a general practitioner does not author complex oncological articles). Patient testimonial workflow routed through the 45 CFR 164.508 consent path before any testimonial lands on a service page.
Monthly

Ongoing retainer

Monthly cadence on the rest of the site, plus content cadence for the queries the diagnostic surfaced. Quarterly review against your traffic data and Search Console movement. Re-audit of the entity-graph reconciliation when physician rosters change. Re-audit of the consent workflow when state medical board advertising rules change.

Common questions

Questions practice administrators ask before booking a diagnostic.

01.

What does dual-threshold YMYL mean for our content architecture?

Google's Reviews System framework scales evaluation threshold by topic stakes. Dermatologic-oncology content (melanoma, basal cell carcinoma, squamous cell carcinoma, Mohs surgery) carries the strictest threshold; the framework reads for practicing-physician reviewer signals, ABMS American Board of Dermatology alignment, fellowship surfacing in the byline body, PubMed primary literature, and specialty-society guideline citations (American Academy of Dermatology clinical guidelines, NCCN oncology guidelines). Cosmetic-dermatology content (injectables, laser treatments, chemical peels) sits at a less-strict threshold but still gates on ABMS alignment. The two thresholds drive two distinct editorial workflows on the same site.

02.

Our dermatologist holds a Mohs fellowship. How does that surface?

The fellowship surfaces in three places. The author byline body names the fellowship (typically as 'Mohs Micrographic Surgery Fellowship, [institution name], [year]'). The Physician.sameAs JSON-LD chain reaches the American College of Mohs Surgery membership page where the fellowship is verifiable, alongside the ABMS American Board of Dermatology verification, NPPES NPI registry, and state medical board licensure profile. The article-to-byline alignment audit pairs Mohs articles with the Mohs-fellowship surgeon and routes non-Mohs dermatology articles to the generalist board-certified dermatologist on staff. Reviews System reads the topic-to-credential alignment per article.

03.

We mention Accutane and Otezla on our condition pages. Are we exposed to FDA?

The dermatology practice marketing its own services is not advertising a prescription drug, and the FDA fair-balance framework does not bind the practice the way it binds the pharmaceutical manufacturer. The moment the page mentions Accutane, Otezla, Dupixent, Rinvoq, Skyrizi, or another prescription drug by trade name in a promotional context, the surface crosses into FDA-regulated promotional copy under 21 CFR 202. The fair-balance requirement applies: efficacy claims pair with risk information. The page architecture separates condition-education content (no trade names, generic-drug-class language) from prescription-drug-mentioning content (fair-balance pattern applied).

04.

How do you handle the cosmetic-vs-medical-dermatology split structurally?

Architecturally, two distinct page sets with distinct schema, distinct byline patterns, and distinct internal-link clusters. Medical-dermatology pages (acne, eczema, psoriasis, skin cancer screening, Mohs surgery) carry MedicalBusiness commercial markup, board-certified-dermatologist bylines for editorial, PubMed-cited primary literature where the article addresses oncologic content. Cosmetic-dermatology pages (Botox, fillers, laser hair removal, chemical peels) carry the same MedicalBusiness commercial markup, with the byline calibrated to the dermatologist (not a general physician) authoring or reviewing the content. The two clusters cross-link only where the medical-dermatology content references a cosmetic offering or vice versa, with explicit framing.

05.

Patient testimonials on dermatology procedures. What governs them?

45 CFR 164.508 written authorization with the five elements: information disclosed, recipient, purpose, expiration, revocation rights. The medical-dermatology testimonials carry HIPAA exposure on identifiable clinical conditions; the cosmetic-dermatology testimonials carry the same HIPAA exposure plus state cosmetic-advertising overlays (Florida testimonial-typicality, California Business and Professions Code disclaimers, Texas Medical Board rules). De-identified case studies for either surface route through the 164.501 + 164.514 Safe Harbor path. AMA E-9.6.1 advertising standards layer on top of all of it.

06.

Does Praxis author the medical-substance content?

We author the SEO architecture, the schema layer, the editorial structure, and the regulatory framing around clinical content. The medical-substance content (condition descriptions, treatment mechanisms, recovery patterns) is authored or reviewed by the ABD-certified dermatologist at the practice, with the author byline reflecting that. Praxis as an entity does not provide medical advice or treatment, and the footer disclaimer states it directly.

Stop watching your competitors rank

If your skin-cancer articles ship under the same byline as your Botox articles, the YMYL threshold is reading them both at the stricter bar.

The diagnostic audits every editorial article against ABMS American Board of Dermatology alignment, every prescription drug trade name against FDA 21 CFR 202 fair-balance, every clinical-condition image against 45 CFR 164.508 specificity, and the per-state cosmetic-advertising overlay for every state the practice operates in.

Book a diagnostic → Email us